عقار الإكينوماسين: رحلة التحديات
DOI:
https://doi.org/10.35516/jjps.v16i3.918الكلمات المفتاحية:
إكينومايسين، روابط مستهدفة، ببتيدات دورية، مضاد حيوي كينوكسالين، مقسم ثنائي الحمض النوويالملخص
الإكينومايسن هو مركب طبيعي تم اكتشافه وعزله من البكتيريا وتم تقديمه كمضاد حيوي وعلاج مضاد للسرطان. ومع ذلك، فقد فشل سريريًا بسبب التركيبات غير الصحيحة وسرعة تحطيمه في الجسم. بعد التجارب السريرية غير الناجحة، تم وقف التجارب السريرية عليه في الآونة الأخيرة، أعطت آلية جديدة بعض الأمل في إحياء مادة الاكينوميسين كمثبط للعامل (HIF-1) ) المحرض لنقص الأكسجين، و في عام 2015 إكينوميسين وصف لعلاج ابيضاض الدم النخاعي الحاد في الولايات المتحدة الأمريكية. علاوة على ذلك، أتاحت التطورات في أنظمة توصيل الأدوية آفاقًا جديدة للتغلب على مشكلات تركيبة الإكينومايسين واستكشاف المزيد من الفوائد العلاجية. توضح هذه المراجعة تفاصيل رحلة إيكينومايسين إلى جانب التحديات الرئيسية لهذا الدواء الفعال وتقدم رؤى حول التطبيقات السريرية المحتملة في المستقبل.
المراجع
Cuesta-Seijo JA., Sheldrick GM. Structures of complexes between echinomycin and duplex DNA. Acta Crystallogr D Biol Crystallogr. 2005; 61(Pt 4): 442-8.
Chung BK., Yudin AK. Disulfide-bridged peptide macrobicycles from nature. Organic & biomolecular chemistry. 2015; 13(33): 8768-79. DOI: https://doi.org/10.1039/C5OB01115A
Wang Y., Liu Y., Malek SN., Zheng P., Liu Y. Targeting HIF1α eliminates cancer stem cells in hematological malignancies. Cell stem cell. 2011; 8(4): 399-411. DOI: https://doi.org/10.1016/j.stem.2011.02.006
Wakelin SP., Waring MJ. The binding of echinomycin to deoxyribonucleic acid. Biochem J. 1976; 157(3): 721-40. DOI: https://doi.org/10.1042/bj1570721
Jarikote DV., Li W., Jiang T., Eriksson LA., Murphy PV. Towards echinomycin mimetics by grafting quinoxaline residues on glycophane scaffolds. Bioorganic & medicinal chemistry. 2011; 19(2): 826-35. DOI: https://doi.org/10.1016/j.bmc.2010.12.009
Gradishar WJ., Vogelzang NJ., Kilton LJ., Leibach SJ., Rademaker AW., French S., et al. A phase II clinical trial of echinomycin in metastatic soft tissue sarcoma. Investigational new drugs. 1995; 13(2): 171-4. DOI: https://doi.org/10.1007/BF00872868
Kong D., Park EJ., Stephen AG., Calvani M., Cardellina JH., Monks A., et al. Echinomycin, a small-molecule inhibitor of hypoxia-inducible factor-1 DNA-binding activity. Cancer research. 2005; 65(19): 9047-55. DOI: https://doi.org/10.1158/0008-5472.CAN-05-1235
Tsuzuki T., Okada H., Shindoh H., Shimoi K., Nishigaki A., Kanzaki H. Effects of the hypoxia-inducible factor-1 inhibitor echinomycin on vascular endothelial growth factor production and apoptosis in human ectopic endometriotic stromal cells. Gynecological Endocrinology. 2016; 32(4): 323-8. DOI: https://doi.org/10.3109/09513590.2015.1121225
Muss HB., Blessing JA., DuBeshter B. Echinomycin in recurrent and metastatic endometrial carcinoma. A phase II trial of the Gynecologic Oncology Group. American journal of clinical oncology. 1993; 16(6): 492-3. DOI: https://doi.org/10.1097/00000421-199312000-00006
Vlaminck B., Toffoli S., Ghislain B., Demazy C., Raes M., Michiels C. Dual effect of echinomycin on hypoxia-inducible factor-1 activity under normoxic and hypoxic conditions. FEBS J. 2007; 274(21): 5533-42. DOI: https://doi.org/10.1111/j.1742-4658.2007.06072.x
Yoshida T., Katagiri K., Yokozawa S. Studies on Quinoxaline Antibiotics. II Isolation and Properties of Quinomycin A, B and C. The Journal of Antibiotics, Series A. 1961; 14(6): 330-4.
Lu Q-P., Ye J-J, Huang Y-M, Liu D, Liu L-F, Dong K, et al. Exploitation of potentially new antibiotics from mangrove actinobacteria in maowei sea by combination of multiple discovery strategies. Antibiotics. 2019; 8(4): 236. DOI: https://doi.org/10.3390/antibiotics8040236
Yoshida T., Katagiri K. Isolation of quinomycin B. The Journal of Antibiotics, Series A. 1962; 15(6): 272.
Waring M., Wakelin L. Echinomycin: a bifunctional intercalating antibiotic. Nature. 1974; 252(5485): 653-7. DOI: https://doi.org/10.1038/252653a0
Dell A., Williams DH., Morris HR., Smith GA., Feeney J., Roberts GC. Structure revision of the antibiotic echinomycin. Journal of the American Chemical Society. 1975; 97(9): 2497-502. DOI: https://doi.org/10.1021/ja00842a029
Van Dyke MM., Dervan PB. Echinomycin binding sites on DNA. Science. 1984; 225(4667): 1122-7. DOI: https://doi.org/10.1126/science.6089341
Ughetto G., Wang AH., Quigley GJ., van der Marel GA., van Boom JH., Rich A. A comparison of the structure of echinomycin and triostin A complexed to a DNA fragment. Nucleic acids research. 1985; 13(7): 2305-23. DOI: https://doi.org/10.1093/nar/13.7.2305
Adams R., Rinaldi A. Effect of echinomycin on DNA methylation. FEBS letters. 1987; 215(2): 266-8. DOI: https://doi.org/10.1016/0014-5793(87)80159-X
Bailly C., Hamy F., Waring MJ. Cooperativity in the binding of echinomycin to DNA fragments containing closely spaced CpG sites. Biochemistry. 1996; 35(4): 1150-61. DOI: https://doi.org/10.1021/bi951696p
Leng F., Chaires JB., Waring MJ. Energetics of echinomycin binding to DNA. Nucleic Acids Research. 2003; 31(21): 6191-7. DOI: https://doi.org/10.1093/nar/gkg826
Wu P-C., Tzeng S-L., Chang C-k., Kao Y-F., Waring MJ., Hou M-H. Cooperative recognition of T: T mismatch by echinomycin causes structural distortions in DNA duplex. Nucleic acids research. 2018; 46(14): 7396-404. DOI: https://doi.org/10.1093/nar/gky345
Yoshida T., Katagiri K., Yokozawa S. Studies on quinoxaline antibiotics. II. Isolation and properties of quinomycins A, B and C. J Antibiot (Tokyo). 1961; 14: 330-4.
Newman R., Fuentes A., Minor T., McManus K., Garteiz D. Determination of echinomycin (NSC-526417) in human plasma: comparison of conventional HPLC to a capillary HPLC, electrospray ionization and mass spectrometry system. Journal of Liquid Chromatography & Related Technologies. 1994; 17(2): 403-17. DOI: https://doi.org/10.1080/10826079408013360
Alshaer W., Odeh, Fadwa, Naffa R., Azzam H., Mahmoud IS., Al Bawab A., Ismail S. Co-encapsulation of thymoquinone with docetaxel enhances the encapsulation efficiency into PEGylated liposomes and the chemosensitivity of MCF7 breast cancer cells to docetaxel. Heliyon. 2019; 5(11): e02919. DOI: https://doi.org/10.1016/j.heliyon.2019.e02919
Katagiri K, Matuura S. [Studies on the antitumor activity of quinoxaline antibiotics]. J Antibiot B. 1963; 16: 122-5.
Cuesta-Seijo JA., Sheldrick GM. Structures of complexes between echinomycin and duplex DNA. Acta Crystallographica Section D: Biological Crystallography. 2005; 61(4): 442-8. DOI: https://doi.org/10.1107/S090744490500137X
Hotta K., Keegan RM., Ranganathan S., Fang M., Bibby J., Winn MD., et al. Conversion of a disulfide bond into a thioacetal group during echinomycin biosynthesis. Angewandte Chemie International Edition. 2014; 53(3): 824-8. DOI: https://doi.org/10.1002/anie.201307404
McNaught AD., Wilkinson A. Compendium of chemical terminology. IUPAC recommendations. 1997.
Corbaz R., Ettlinger L., Gäumann E., Schierlein WK., Kradolfer F., Neipp L., et al. Stoffwechselprodukte von actinomyceten. 7. mitteilung. echinomycin. Helvetica Chimica Acta. 1957; 40(1): 199-204. DOI: https://doi.org/10.1002/hlca.19570400124
Steinerova N., Lipavska H., Stajner K., Čáslavská J., Blumauerova M., Cudlin J., et al. Production of quinomycin A inStreptomyces lasaliensis. Folia microbiologica. 1987; 32(1): 1-5. DOI: https://doi.org/10.1007/BF02877251
Watanabe K., Hotta K., Praseuth AP., Koketsu K., Migita A., Boddy CN., et al. Total biosynthesis of antitumor nonribosomal peptides in Escherichia coli. Nature chemical biology. 2006; 2(8): 423-8. DOI: https://doi.org/10.1038/nchembio803
Watanabe K., Oguri H., Oikawa H. Diversification of echinomycin molecular structure by way of chemoenzymatic synthesis and heterologous expression of the engineered echinomycin biosynthetic pathway. Current opinion in chemical biology. 2009; 13(2): 189-96. DOI: https://doi.org/10.1016/j.cbpa.2009.02.012
Sato M., Nakazawa T., Tsunematsu Y., Hotta K., Watanabe K. Echinomycin biosynthesis. Current opinion in chemical biology. 2013; 17(4): 537-45. DOI: https://doi.org/10.1016/j.cbpa.2013.06.022
Kojima K., Yakushiji F., Katsuyama A., Ichikawa S. Total Synthesis of Echinomycin and Its Analogues. Organic letters. 2020; 22(11): 4217-21. DOI: https://doi.org/10.1021/acs.orglett.0c01268
Duan N., Wu S., Dai S., Gu H., Hao L., Ye H., et al. Advances in aptasensors for the detection of food contaminants. Analyst. 2016; 141(13): 3942-61. DOI: https://doi.org/10.1039/C6AN00952B
Lafi Z., Aboalhaija N., Afifi F. Ethnopharmacological importance of local flora in the traditional medicine of Jordan:(A mini review). Jordan Journal of Pharmaceutical Sciences. 2022; 15(1): 132-44. DOI: https://doi.org/10.35516/jjps.v15i1.300
White RJ., Phillips DR. Bidirectional transcription footprinting of DNA binding ligands. Biochemistry. 1989; 28(15): 6259-69. DOI: https://doi.org/10.1021/bi00441a018
Yonekura S., Itoh M., Okuhashi Y., Takahashi Y., Ono A., Nara N., et al. Effects of the HIF1 inhibitor, echinomycin, on growth and NOTCH signalling in leukaemia cells. Anticancer research. 2013; 33(8): 3099-103.
Plastino F., Santana-Garrido Á., Pesce NA., Aronsson M., Lardner E., Mate A., et al. Echinomycin mitigates ocular angiogenesis by transcriptional inhibition of the hypoxia-inducible factor-1. Experimental Eye Research. 2021; 206: 108518. DOI: https://doi.org/10.1016/j.exer.2021.108518
Park JY., Park SJ., Shim KY., Lee KJ., Kim Y-B., Kim YH., et al. Echinomycin and a novel analogue induce apoptosis of HT-29 cells via the activation of MAP kinases pathway. Pharmacological research. 2004; 50(2): 201-7. DOI: https://doi.org/10.1016/j.phrs.2004.01.005
Lee H-C., Tsai S-J. Endocrine targets of hypoxia-inducible factors. The Journal of endocrinology. 2017; 234(1): R53-R65. DOI: https://doi.org/10.1530/JOE-16-0653
Park Y-S., Shin W-S., Kim S-K. In vitro and in vivo activities of echinomycin against clinical isolates of Staphylococcus aureus. Journal of antimicrobial chemotherapy. 2008; 61(1): 163-8.
Donald RG., Skwish S., Forsyth RA., Anderson JW., Zhong T., Burns C., et al. A Staphylococcus aureus fitness test platform for mechanism-based profiling of antibacterial compounds. Chemistry & biology. 2009; 16(8): 826-36. DOI: https://doi.org/10.1016/j.chembiol.2009.07.004
Park YS., Shin WS., Kim SK. In vitro and in vivo activities of echinomycin against clinical isolates of Staphylococcus aureus. J Antimicrob Chemother. 2008; 61(1): 163-8. DOI: https://doi.org/10.1093/jac/dkm421
Kim JB., Lee GS., Kim YB., Kim SK., Kim YH. In vitro antibacterial activity of echinomycin and a novel analogue, YK2000, against vancomycin-resistant enterococci. Int J Antimicrob Agents. 2004; 24(6): 613-5.
Socha AM., LaPlante KL., Russell DJ., Rowley DC. Structure–activity studies of echinomycin antibiotics against drug-resistant and biofilm-forming Staphylococcus aureus and Enterococcus faecalis. Bioorganic & medicinal chemistry letters. 2009; 19(5): 1504-7. DOI: https://doi.org/10.1016/j.bmcl.2009.01.010
Muss HB., Blessing JA., Baker VV., Barnhill DR., Adelson MD. Echinomycin (NSC 526417) in advanced ovarian cancer. A phase II trial of the Gynecologic Oncology Group. American journal of clinical oncology. 1990; 13(4): 299-301. DOI: https://doi.org/10.1097/00000421-199008000-00006
Muss HB., Blessing JA., Hanjani P., Malfetano JH., Kemp GM., Webster K. Echinomycin (NSC 526417) in recurrent and metastatic nonsquamous cell carcinoma of the cervix. A phase II trial of the Gynecologic Oncology Group. American journal of clinical oncology. 1992; 15(4): 363-4. DOI: https://doi.org/10.1097/00000421-199208000-00019
Lathan B, Von hoff dd. Cytotoxic activity of echinomycin in a human tumor cloning system. Cancer drug delivery. 1984; 1(3): 191-8. DOI: https://doi.org/10.1089/cdd.1984.1.191
Foster BJ., Clagett-Carr K., Shoemaker DD., Suffness M., Plowman J., Trissel LA., et al. Echinomycin: the first bifunctional intercalating agent in clinical trials. Investigational new drugs. 1985; 3(4): 403-10. DOI: https://doi.org/10.1007/BF00170766
Pazdur R., Haas CD., Baker LH., Leichman CG., Decker D. Phase I Study of Echinomycin 1, 2. Cancer treatment reports. 1987; 71(12): 1217.
Kuhn JG., Von Hoff DD., Hersh M., Melink T., Clark GM., Weiss GR., et al. Phase I trial of echinomycin (NSC 526417), a bifunctional intercalating agent, administered by 24-hour continuous infusion. European Journal of Cancer and Clinical Oncology. 1989; 25(5): 797-803. DOI: https://doi.org/10.1016/0277-5379(89)90123-5
Hakes T., Markman M., Phillips M. A phase II trial of echinomycin in metastatic cervix carcinoma. Investigational new drugs. 1990; 8(3): 311-2. DOI: https://doi.org/10.1007/BF00171844
Brown TD., Goodman PJ., Fleming TR., Taylor SA., Macdonald JS. Phase II trial of echinomycin in advanced colorectal cancer: a southwest oncology group study. Investigational new drugs. 1991; 9(1): 113-4. DOI: https://doi.org/10.1007/BF00194561
Schilsky RL., Faraggi D., Korzun A., Vogelzang N., Ellerton J., Wood W., et al. Phase II study of echinomycin in patients with advanced breast cancer: a report of Cancer and Leukemia Group B protocol 8641. Investigational new drugs. 1991; 9(3): 269-72. DOI: https://doi.org/10.1007/BF00176982
Chang AY., Tu ZN., Bryan GT., Kirkwood JM., Oken MM., Trump DL. Phase II study of echinomycin in the treatment of renal cell carcinoma ECOG study E2885. Investigational new drugs. 1994; 12(2): 151-3. DOI: https://doi.org/10.1007/BF00874447
Wadler S., Tenteromano L., Cazenave L., Sparano JA., Greenwald ES., Rozenblit A., et al. Phase II trial of echinomycin in patients with advanced or recurrent colorectal cancer. Cancer chemotherapy and pharmacology. 1994; 34(3): 266-9. DOI: https://doi.org/10.1007/BF00685088
Chang AY., Kim K., Boucher H., Bonomi P., Stewart JA., Karp DD., et al. A randomized phase II trial of echinomycin, trimetrexate, and cisplatin plus etoposide in patients with metastatic nonsmall cell lung carcinoma: an Eastern Cooperative Oncology Group Study (E1587). Cancer: Interdisciplinary International Journal of the American Cancer Society. 1998; 82(2): 292-300. DOI: https://doi.org/10.1002/(SICI)1097-0142(19980115)82:2<301::AID-CNCR8>3.0.CO;2-T
Park YS., Kim YH., Kim SK., Choi S-J. A new antitumor agent: methyl sulfonium perchlorate of echinomycin. Bioorganic & medicinal chemistry letters. 1998; 8(7): 731-4. DOI: https://doi.org/10.1016/S0960-894X(98)00113-9
May LG., Madine MA., Waring MJ. Echinomycin inhibits chromosomal DNA replication and embryonic development in vertebrates. Nucleic acids research. 2004; 32(1): 65-72. DOI: https://doi.org/10.1093/nar/gkh166
Kim J-B., Lee G-S., Kim Y-B., Kim S-K., Kim YH. In vitro antibacterial activity of echinomycin and a novel analogue, YK2000, against vancomycin-resistant enterococci. International journal of antimicrobial agents. 2004; 24(6): 613-5. DOI: https://doi.org/10.1016/j.ijantimicag.2004.03.018
Lee Y-K., Park JH., Moon HT., Lee DY., Yun JH., Byun Y. The short-term effects on restenosis and thrombosis of echinomycin-eluting stents topcoated with a hydrophobic heparin-containing polymer. Biomaterials. 2007; 28(8): 1523-30. DOI: https://doi.org/10.1016/j.biomaterials.2006.11.020
Wang Z., Zhang Z., Wu Y., Chen L., Luo Q., Zhang J., et al. Effects of echinomycin on endothelin-2 expression and ovulation in immature rats primed with gonadotropins. Experimental & molecular medicine. 2012; 44(10): 615-21. DOI: https://doi.org/10.3858/emm.2012.44.10.070
Zimmermann S., Würgler-Hauri C., Wanner G., Simmen H., Werner C. Echinomycin in the prevention of heterotopic ossification–an experimental antibiotic agent shows promising results in a murine model. Injury. 2013; 44(4): 570-5. DOI: https://doi.org/10.1016/j.injury.2012.12.030
Singh V., Nand A., Chen C., Li Z., Li S-J., Wang S., et al. Echinomycin, a potential binder of FKBP12, shows minor effect on calcineurin activity. Journal of biomolecular screening. 2014; 19(9): 1275-81. DOI: https://doi.org/10.1177/1087057114544742
Wang Y., Liu Y., Tang F., Bernot KM., Schore R., Marcucci G., et al. Echinomycin protects mice against relapsed acute myeloid leukemia without adverse effect on hematopoietic stem cells. Blood, The Journal of the American Society of Hematology. 2014; 124(7): 1127-35. DOI: https://doi.org/10.1182/blood-2013-12-544221
Ponnurangam S., Dandawate PR., Dhar A., Tawfik OW., Parab RR., Mishra PD., et al. Quinomycin A targets Notch signaling pathway in pancreatic cancer stem cells. Oncotarget. 2016; 7(3): 3217. DOI: https://doi.org/10.18632/oncotarget.6560
Zhang Z., Chen J., Tang Z., Lin Q., Wang Z., editors. Effects of Echinomycin on Follicular Development in the Ovary of Postnatal Rats. 2015 7th International Conference on Information Technology in Medicine and Education (ITME); 2015: IEEE. DOI: https://doi.org/10.1109/ITME.2015.121
Yamaguchi J., Tanaka T., Saito H., Nomura S., Aburatani H., Waki H., et al. Echinomycin inhibits adipogenesis in 3T3-L1 cells in a HIF-independent manner. Scientific reports. 2017; 7(1): 1-13. DOI: https://doi.org/10.1038/s41598-017-06761-4
Liu Y., Wang Y., Liu Y., Bailey C., Zheng P. Echinomycin formulation, method of making and method of use thereof. Google Patents; 2021.
Kwon D., Liew H. miRNA profile of neuroprotection mechanism of echinomycin in Parkinson’s disease. Molecular & Cellular Toxicology. 2017; 13(2): 229-38. DOI: https://doi.org/10.1007/s13273-017-0025-6
Wang Y., Bailey C., Liu Y., Zheng P., Liu Y. PC-2 A liposomal formulation of HIF-1α inhibitor echinomycin inhibits growth and metastasis of experimental model of breast cancer. JAIDS Journal of Acquired Immune Deficiency Syndromes. 2019; 81:58. DOI: https://doi.org/10.1097/01.qai.0000558005.23515.7b
Baumeister J., Chatain N., Hubrich A., Maié T., Costa IG., Denecke B., et al. Hypoxia-inducible factor 1 (HIF-1) is a new therapeutic target in JAK2 V617F-positive myeloproliferative neoplasms. Leukemia. 2020; 34(4): 1062-74. DOI: https://doi.org/10.1038/s41375-019-0629-z
Bailey CM., Liu Y., Peng G., Zhang H., He M., Sun D., et al. Liposomal formulation of HIF-1α inhibitor echinomycin eliminates established metastases of triple-negative breast cancer. Nanomedicine: Nanotechnology, Biology and Medicine. 2020; 29: 102278. DOI: https://doi.org/10.1016/j.nano.2020.102278
Thomas A., Samykutty A., Gomez-Gutierrez JG., Yin W., Egger ME., McNally M., et al. Actively targeted nanodelivery of echinomycin induces autophagy-mediated death in chemoresistant pancreatic cancer in vivo. Cancers. 2020; 12(8): 2279. DOI: https://doi.org/10.3390/cancers12082279
Huang X., Liu Y., Wang Y., Bailey C., Zheng P., Liu Y. Dual Targeting Oncoproteins MYC and HIF1α Regresses Tumor Growth of Lung Cancer and Lymphoma. Cancers. 2021; 13(4): 694. DOI: https://doi.org/10.3390/cancers13040694
Lafi Z., Alshaer W., Ma'mon MH., Zihlif M., Alqudah DA., Nsairat H., et al. Aptamer-functionalized pH-sensitive liposomes for a selective delivery of echinomycin into cancer cells. RSC Advances. 2021; 11(47): 29164-77. DOI: https://doi.org/10.1039/D1RA05138E
Gelderblom H., Verweij J., Nooter K., Sparreboom A. Cremophor EL: the drawbacks and advantages of vehicle selection for drug formulation. European journal of cancer. 2001; 37(13): 1590-8. DOI: https://doi.org/10.1016/S0959-8049(01)00171-X
Kzar HH., Al-Gazally ME., Wtwt MA. Everolimus loaded NPs with FOL targeting: preparation, characterization and study of its cytotoxicity action on MCF-7 breast cancer cell lines. Jordan Journal of Pharmaceutical Sciences. 2022; 15(1): 25-39. DOI: https://doi.org/10.35516/jjps.v15i1.286
Zhao P., Astruc D. Docetaxel nanotechnology in anticancer therapy. ChemMedChem. 2012; 7(6): 952. DOI: https://doi.org/10.1002/cmdc.201200052
Alshaer W., Zraikat M., Amer A., Nsairat H., Lafi Z., Alqudah DA., et al. Encapsulation of echinomycin in cyclodextrin inclusion complexes into liposomes: in vitro anti-proliferative and anti-invasive activity in glioblastoma. RSC advances. 2019; 9(53): 30976-88. DOI: https://doi.org/10.1039/C9RA05636J
